サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1472260

HIV注射市場：流通チャネル別：世界の機会分析と産業予測、2024～2033年

HIV Injection Market By Distribution Channel (Hospital Pharmacy, Drugs Stores and Retail Pharmacies, Others): Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 197 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
HIV注射市場：流通チャネル別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年02月01日
発行: Allied Market Research
ページ情報: 英文 197 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

HIV注射市場は、2023年には10億米ドルとなり、2024年から2033年までのCAGRは17.9%を示し、2033年までには55億米ドルに達すると推定されています。

ヒト免疫不全ウイルス（HIV）は、免疫系、特に免疫系が感染症を撃退するのを助けるCD4細胞（T細胞）を攻撃するウイルスです。HIVは主に、無防備な性交渉、汚染された注射針の共有、出産や授乳中に感染した母親から赤ちゃんに感染します。抗レトロウイルス療法（ART）の進歩は、HIVとともに生きる人々の予後を著しく改善し、ウイルスを制御し、AIDSへの進行を防ぎ、生活の質全体を高めるのに役立っています。定期的な検査、早期発見、医療へのアクセスは、HIVを管理し、蔓延を予防する上で極めて重要です。

HIV Injection Market-IMG1

この感染症と闘うための世界の努力には、一般の人々の認識、教育、継続的な研究が不可欠です。HIV注射は、抗レトロウイルス薬を血流に直接送り込み、体内の薬物濃度を効果的かつ一定に保つように設計されています。これらの注射には、筋肉内注射（筋肉に投与）や皮下注射（皮膚のすぐ下に投与）など、さまざまな形態があります。HIV注射市場は、HIV感染者数の増加、注射製剤の新規抗レトロウイルス薬の開発・インダクション、長時間作用型・長時間デリバリー型のHIV予防・治療レジメンに対する需要の増加、研究開発活動への投資の増加、HIVに対する政府の取り組みや医療政策の拡大などによって牽引されています。

例えば、国連エイズ合同計画（UNAIDS）によると、2022年には世界で3,900万人がHIVとともに生活しています。したがって、HIV感染者数の増加はHIV注射の需要を増加させ、市場の成長を促進します。加えて、HIV治療分野での継続的な研究開発努力により、継続的な進歩がもたらされ、市場成長の促進力となることが期待されます。新しい抗レトロウイルス薬、特に注射剤の導入は、医療従事者や患者にウイルス管理のためのより多くの選択肢を提供し、それによって市場の成長を促進します。例えば、GlaxoSmithKline plc companyは、カボテグラビルとリルピビリンを配合したHIV治療用の長時間作用型注射抗レトロウイルス薬を製造しました。このレジメンはカベヌバ（欧州ではボカブリア、レカンビス）として知られ、インテグラーゼ阻害剤であるカボテグラビルと非ヌクレオシド系逆転写酵素阻害剤であるリルピビリンを筋肉注射します。この長時間作用型の注射レジメンは、いくつかの高所得国で承認されており、ウイルス抑制の維持に有望視されています。

さらに、HIV治療へのアクセスを拡大し、ヘルスケア・インフラを改善することを目的とした政府の取り組みやヘルスケア政策が極めて重要な役割を果たしており、これが市場の成長を促進すると期待されています。例えば、米国保健社会福祉省（HHS）が主導する「HIV流行終息（Ending the HIV Epidemic：EHE）」イニシアチブは、米国における新規HIV感染者数を2025年までに75％削減し、2030年までに少なくとも90％削減することを目標としています。HHSは、HIVの予防、診断、治療、発生時の対応における科学的進歩を活用し、人種的、民族的、地理的格差に対処することに重点を置いています。

しかし、認可のための規制プロセスが厳しいことや、低開発国におけるHIV予防に関する教育不足が、HIV注射市場の成長を阻害する要因となっています。これとは対照的に、HIV治療薬のパイプラインの増加や新興国における高い潜在成長力は、市場成長に有利な機会を提供しています。例えば、臨床段階の免疫療法企業であるImmunityBio, Inc.は、2021年6月、米国で参加者を登録中のAnktiva（N-803）を用いたHIV治癒試験によるHIV臨床パイプラインを発表しました。この試験では、参加者が抗レトロウイルス療法（ART）を中止し、注意深くモニターされた後、Anktivaが単独で、または併用中和抗体（bNAB）と共にHIVを制御できるかどうかを検討することが期待されています。

HIV注射市場は、流通チャネルと地域によって区分されます。流通チャネル別では、市場は病院薬局、ドラッグストアおよび小売薬局、その他に分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州地域）、アジア太平洋（日本、中国、インド、オーストラリア、韓国、その他アジア太平洋）、ラテンアメリカ、中東・アフリカ （ブラジル、中国、アフリカ、アラビア、その他ラテンアメリカ、中東・アフリカ）で分析されます。

利害関係者にとっての主なメリット

  • 当レポートでは、2023年から2033年にかけてのHIV注射市場分析の市場セグメント、現在の動向、推定・動向、ダイナミクスを定量的に分析し、HIV注射市場の有力な機会を特定します。
  • 市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
  • ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるように、バイヤーとサプライヤーの潜在力を強調します。
  • HIV注射の市場セグメンテーションを詳細に分析することで、市場機会を見極めることができます。
  • 各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
  • 市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
  • 本レポートには、地域別および世界のHIV注射市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。

レポートカスタマイズの可能性（追加費用とタイムラインに関しましては販売担当へご連絡ください）

  • 国、地域、世界レベルでの患者 / 疫学データ
  • 規制ガイドライン
  • クライアントの関心に応じた追加企業プロファイル
  • 国別または地域別追加分析 - 市場規模と予測
  • クリスクロスセグメント分析 - 市場規模と予測
  • 企業プロファイルの拡張リスト
  • 過去の市場データ
  • SWOT分析

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主要な影響要因
    • 主要な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
      • HIV治療を受ける人の増加
      • HIVに対する政府の認識とイニシアチブの高まり
      • 製品承認数の増加
    • 抑制要因
      • 承認のための厳しい規制プロセス
    • 機会
      • 新興市場における高い成長の可能性
      • パイプライン製品の増加

第4章 HIV注射市場：流通チャネル別

  • 概要
  • 病院薬局
  • ドラッグストア・小売薬局
  • その他

第5章 HIV注射市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋
  • ラテンアメリカ、中東・アフリカ
    • ブラジル
    • サウジアラビア
    • 南アフリカ
    • その他ラテンアメリカ、中東・アフリカ

第6章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2023年

第7章 企業プロファイル

  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • ImmunityBio, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Theratechnologies Inc.
  • Viriom, Inc.
  • AbbVie Inc.
  • Brii Biosciences
  • Shionogi & Co., Ltd.
図表

LIST OF TABLES

  • TABLE 01. GLOBAL HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 02. HIV INJECTION MARKET FOR HOSPITAL PHARMACY, BY REGION, 2023-2033 ($MILLION)
  • TABLE 03. HIV INJECTION MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY REGION, 2023-2033 ($MILLION)
  • TABLE 04. HIV INJECTION MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 05. HIV INJECTION MARKET, BY REGION, 2023-2033 ($MILLION)
  • TABLE 06. NORTH AMERICA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 07. NORTH AMERICA HIV INJECTION MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 08. U.S. HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 09. CANADA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 10. MEXICO HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 11. EUROPE HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 12. EUROPE HIV INJECTION MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 13. GERMANY HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 14. FRANCE HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 15. UK HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 16. ITALY HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 17. SPAIN HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 18. REST OF EUROPE HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 19. ASIA-PACIFIC HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 20. ASIA-PACIFIC HIV INJECTION MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 21. JAPAN HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 22. CHINA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 23. INDIA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 24. AUSTRALIA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 25. SOUTH KOREA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 26. REST OF ASIA-PACIFIC HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 27. LAMEA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 28. LAMEA HIV INJECTION MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 29. BRAZIL HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 30. SAUDI ARABIA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 31. SOUTH AFRICA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 32. REST OF LAMEA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 33. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 34. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 35. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 36. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 37. GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 38. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 39. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 40. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 41. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 42. JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 43. GILEAD SCIENCES, INC.: KEY EXECUTIVES
  • TABLE 44. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 45. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
  • TABLE 46. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 47. GILEAD SCIENCES, INC.: KEY STRATERGIES
  • TABLE 48. IMMUNITYBIO, INC.: KEY EXECUTIVES
  • TABLE 49. IMMUNITYBIO, INC.: COMPANY SNAPSHOT
  • TABLE 50. IMMUNITYBIO, INC.: PRODUCT SEGMENTS
  • TABLE 51. IMMUNITYBIO, INC.: PRODUCT PORTFOLIO
  • TABLE 52. IMMUNITYBIO, INC.: KEY STRATERGIES
  • TABLE 53. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 54. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 55. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 56. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 57. THERATECHNOLOGIES INC.: KEY EXECUTIVES
  • TABLE 58. THERATECHNOLOGIES INC.: COMPANY SNAPSHOT
  • TABLE 59. THERATECHNOLOGIES INC.: PRODUCT SEGMENTS
  • TABLE 60. THERATECHNOLOGIES INC.: PRODUCT PORTFOLIO
  • TABLE 61. THERATECHNOLOGIES INC.: KEY STRATERGIES
  • TABLE 62. VIRIOM, INC.: KEY EXECUTIVES
  • TABLE 63. VIRIOM, INC.: COMPANY SNAPSHOT
  • TABLE 64. VIRIOM, INC.: PRODUCT SEGMENTS
  • TABLE 65. VIRIOM, INC.: PRODUCT PORTFOLIO
  • TABLE 66. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 67. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 68. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 69. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 70. BRII BIOSCIENCES: KEY EXECUTIVES
  • TABLE 71. BRII BIOSCIENCES: COMPANY SNAPSHOT
  • TABLE 72. BRII BIOSCIENCES: PRODUCT SEGMENTS
  • TABLE 73. BRII BIOSCIENCES: PRODUCT PORTFOLIO
  • TABLE 74. SHIONOGI & CO., LTD.: KEY EXECUTIVES
  • TABLE 75. SHIONOGI & CO., LTD.: COMPANY SNAPSHOT
  • TABLE 76. SHIONOGI & CO., LTD.: PRODUCT SEGMENTS
  • TABLE 77. SHIONOGI & CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 78. SHIONOGI & CO., LTD.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. HIV INJECTION MARKET, 2023-2033
  • FIGURE 02. SEGMENTATION OF HIV INJECTION MARKET,2023-2033
  • FIGURE 03. TOP IMPACTING FACTORS IN HIV INJECTION MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN HIV INJECTION MARKET (2024-2033)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL HIV INJECTION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023 AND 2033(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HIV INJECTION MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF HIV INJECTION MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF HIV INJECTION MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 15. HIV INJECTION MARKET BY REGION, 2023 AND 2033(%)
  • FIGURE 16. U.S. HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 17. CANADA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 18. MEXICO HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 19. GERMANY HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 20. FRANCE HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 21. UK HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 22. ITALY HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 23. SPAIN HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 24. REST OF EUROPE HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 25. JAPAN HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 26. CHINA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 27. INDIA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 28. AUSTRALIA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 29. SOUTH KOREA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 30. REST OF ASIA-PACIFIC HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 31. BRAZIL HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 32. SAUDI ARABIA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 33. SOUTH AFRICA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 34. REST OF LAMEA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 35. TOP WINNING STRATEGIES, BY YEAR (2021-2023)
  • FIGURE 36. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2023)
  • FIGURE 37. TOP WINNING STRATEGIES, BY COMPANY (2021-2023)
  • FIGURE 38. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 39. COMPETITIVE DASHBOARD
  • FIGURE 40. COMPETITIVE HEATMAP: HIV INJECTION MARKET
  • FIGURE 41. TOP PLAYER POSITIONING, 2023
  • FIGURE 42. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 44. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 45. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 47. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 48. GILEAD SCIENCES, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 49. IMMUNITYBIO, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. IMMUNITYBIO, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 51. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. THERATECHNOLOGIES INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. THERATECHNOLOGIES INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. BRII BIOSCIENCES: NET REVENUE, 2022-2022 ($MILLION)
  • FIGURE 59. SHIONOGI & CO., LTD.: NET REVENUE, 2021-2023 ($MILLION)
目次
Product Code: A312373

The HIV injection market was valued at $1 billion in 2023 and is estimated to reach $5.5 billion by 2033, exhibiting a CAGR of 17.9% from 2024 to 2033. Human immunodeficiency virus (HIV) is a virus that attacks the immune system, specifically the CD4 cells (T cells), which help the immune system fight off infections. HIV is primarily transmitted through unprotected sexual intercourse, sharing of contaminated needles, and from an infected mother to her baby during childbirth or breastfeeding. Advances in antiretroviral therapy (ART) have significantly improved the prognosis for people living with HIV, helping to control the virus, prevent the progression to AIDS, and enhance overall quality of life. Regular testing, early detection, and access to medical care are crucial in managing and preventing the spread of HIV.

HIV Injection Market - IMG1

Public awareness, education, and ongoing research remain essential in the global effort to combat this infectious disease. HIV injections are designed to deliver antiretroviral drugs directly into the bloodstream, ensuring effective and consistent levels of the medication in the body. These injections can come in various forms, including intramuscular injections (administered into the muscle) or subcutaneous injections (administered just beneath the skin). The HIV injection market is driven by rise in the number of people suffering from HIV, development and introduction of novel antiretroviral drugs in injectable formulations, rise in demand for long acting and extended delivery HIV prevention and treatment regimens, rise in investment in R and D activities, and growing government initiatives and healthcare policies for HIV.

For instance, according to the Joint United Nations Program on HIV and AIDS (UNAIDS), 39 million people globally were living with HIV in 2022. Thus, rise in the number of HIV cases increases the demand for HIV injections and drives the growth of market. In addition, ongoing R and D efforts in the field of HIV treatment led to continuous advancements which is expected to drive the market growth. The introduction of novel antiretroviral drugs, particularly those in injectable formulations, provides healthcare providers and patients with more options for managing the virus, thereby driving market growth. For instance, GlaxoSmithKline plc company manufactured combination of cabotegravir and rilpivirine, a long-acting injectable antiretroviral drug for the treatment of HIV. This regimen, known as Cabenuva (Vocabria and Rekambys in Europe), involves the intramuscular injection of cabotegravir, an integrase inhibitor, and rilpivirine, a non-nucleoside reverse transcriptase inhibitor. This long-acting injectable regimen has been approved in several high-income countries and has shown promise in maintaining viral suppression.

Furthermore, the government initiatives and healthcare policies, aimed at expanding access to HIV treatment and improving healthcare infrastructure, play a pivotal role, which is expected to drive the market growth. For instance, Ending the HIV Epidemic (EHE) initiative, coordinated by the U.S. Department of Health and Human Services (HHS) aims to reduce the number of new HIV infections in the U.S. by 75% by 2025 and then by at least 90% by 2030. It focuses on leveraging scientific advances in HIV prevention, diagnosis, treatment, and outbreak response to address racial, ethnic, and geographic disparities.

However, the stringent regulatory process for approval and lack of education about HIV prevention in underdeveloped countries are factors responsible for impeding the growth of the HIV injection market. In contrast, rise in number of pipeline drugs for HIV and high growth potential in emerging countries provides lucrative opportunity to the market growth. For instance, in June 2021, ImmunityBio, Inc., a clinical-stage immunotherapy company, announced its HIV clinical pipeline with an HIV cure study using Anktiva (N-803), which is now enrolling participants in the U.S. The trial is expected to study whether Anktiva can control HIV alone or together with combination broadly neutralizing antibodies (bNABs) after participants stop their antiretroviral therapy (ART) and they are carefully monitored.

The HIV injection market is segmented on the basis of distribution channel and region. By distribution channel, the market is classified into hospital pharmacy, drug stores and retail pharmacy, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global HIV injection market are GlaxoSmithKline plc, Johnson and Johnson, Gilead Sciences, Inc., ImmunityBio, Inc., F. Hoffmann-La Roche Ltd, Theratechnologies Inc., Viriom, Inc., Shionogi & Co., Ltd., AbbVie Inc., and Brii Biosciences. Key players operating in the market have adopted product approvals, partnership, expansion, agreement, and clinical trial as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hiv injection market analysis from 2023 to 2033 to identify the prevailing hiv injection market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the hiv injection market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global hiv injection market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Distribution Channel

  • Others
  • Hospital Pharmacy
  • Drugs Stores and Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Gilead Sciences, Inc.
    • F. Hoffmann-La Roche Ltd.
    • AbbVie Inc.
    • Shionogi & Co., Ltd.
    • ImmunityBio, Inc.
    • Theratechnologies Inc.
    • Viriom, Inc.
    • Brii Biosciences

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in number of people receiving HIV therapy
      • 3.4.1.2. Growing awareness & initiatives taken by government for HIV
      • 3.4.1.3. Rise in number of product approvals
    • 3.4.2. Restraints
      • 3.4.2.1. Stringent regulatory processes for the approval
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in emerging markets
      • 3.4.3.2. Rise in number of pipeline products

CHAPTER 4: HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Hospital Pharmacy
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Drugs Stores and Retail Pharmacies
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: HIV INJECTION MARKET, BY REGION

  • 5.1. Overview
    • 5.1.1. Market size and forecast By Region
  • 5.2. North America
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by Distribution Channel
    • 5.2.3. Market size and forecast, by country
      • 5.2.3.1. U.S.
      • 5.2.3.1.1. Market size and forecast, by Distribution Channel
      • 5.2.3.2. Canada
      • 5.2.3.2.1. Market size and forecast, by Distribution Channel
      • 5.2.3.3. Mexico
      • 5.2.3.3.1. Market size and forecast, by Distribution Channel
  • 5.3. Europe
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by Distribution Channel
    • 5.3.3. Market size and forecast, by country
      • 5.3.3.1. Germany
      • 5.3.3.1.1. Market size and forecast, by Distribution Channel
      • 5.3.3.2. France
      • 5.3.3.2.1. Market size and forecast, by Distribution Channel
      • 5.3.3.3. UK
      • 5.3.3.3.1. Market size and forecast, by Distribution Channel
      • 5.3.3.4. Italy
      • 5.3.3.4.1. Market size and forecast, by Distribution Channel
      • 5.3.3.5. Spain
      • 5.3.3.5.1. Market size and forecast, by Distribution Channel
      • 5.3.3.6. Rest of Europe
      • 5.3.3.6.1. Market size and forecast, by Distribution Channel
  • 5.4. Asia-Pacific
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by Distribution Channel
    • 5.4.3. Market size and forecast, by country
      • 5.4.3.1. Japan
      • 5.4.3.1.1. Market size and forecast, by Distribution Channel
      • 5.4.3.2. China
      • 5.4.3.2.1. Market size and forecast, by Distribution Channel
      • 5.4.3.3. India
      • 5.4.3.3.1. Market size and forecast, by Distribution Channel
      • 5.4.3.4. Australia
      • 5.4.3.4.1. Market size and forecast, by Distribution Channel
      • 5.4.3.5. South Korea
      • 5.4.3.5.1. Market size and forecast, by Distribution Channel
      • 5.4.3.6. Rest of Asia-Pacific
      • 5.4.3.6.1. Market size and forecast, by Distribution Channel
  • 5.5. LAMEA
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by Distribution Channel
    • 5.5.3. Market size and forecast, by country
      • 5.5.3.1. Brazil
      • 5.5.3.1.1. Market size and forecast, by Distribution Channel
      • 5.5.3.2. Saudi Arabia
      • 5.5.3.2.1. Market size and forecast, by Distribution Channel
      • 5.5.3.3. South Africa
      • 5.5.3.3.1. Market size and forecast, by Distribution Channel
      • 5.5.3.4. Rest of LAMEA
      • 5.5.3.4.1. Market size and forecast, by Distribution Channel

CHAPTER 6: COMPETITIVE LANDSCAPE

  • 6.1. Introduction
  • 6.2. Top winning strategies
  • 6.3. Product mapping of top 10 player
  • 6.4. Competitive dashboard
  • 6.5. Competitive heatmap
  • 6.6. Top player positioning, 2023

CHAPTER 7: COMPANY PROFILES

  • 7.1. GlaxoSmithKline plc
    • 7.1.1. Company overview
    • 7.1.2. Key executives
    • 7.1.3. Company snapshot
    • 7.1.4. Operating business segments
    • 7.1.5. Product portfolio
    • 7.1.6. Business performance
    • 7.1.7. Key strategic moves and developments
  • 7.2. Johnson & Johnson
    • 7.2.1. Company overview
    • 7.2.2. Key executives
    • 7.2.3. Company snapshot
    • 7.2.4. Operating business segments
    • 7.2.5. Product portfolio
    • 7.2.6. Business performance
    • 7.2.7. Key strategic moves and developments
  • 7.3. Gilead Sciences, Inc.
    • 7.3.1. Company overview
    • 7.3.2. Key executives
    • 7.3.3. Company snapshot
    • 7.3.4. Operating business segments
    • 7.3.5. Product portfolio
    • 7.3.6. Business performance
    • 7.3.7. Key strategic moves and developments
  • 7.4. ImmunityBio, Inc.
    • 7.4.1. Company overview
    • 7.4.2. Key executives
    • 7.4.3. Company snapshot
    • 7.4.4. Operating business segments
    • 7.4.5. Product portfolio
    • 7.4.6. Business performance
    • 7.4.7. Key strategic moves and developments
  • 7.5. F. Hoffmann-La Roche Ltd.
    • 7.5.1. Company overview
    • 7.5.2. Key executives
    • 7.5.3. Company snapshot
    • 7.5.4. Operating business segments
    • 7.5.5. Product portfolio
    • 7.5.6. Business performance
  • 7.6. Theratechnologies Inc.
    • 7.6.1. Company overview
    • 7.6.2. Key executives
    • 7.6.3. Company snapshot
    • 7.6.4. Operating business segments
    • 7.6.5. Product portfolio
    • 7.6.6. Business performance
    • 7.6.7. Key strategic moves and developments
  • 7.7. Viriom, Inc.
    • 7.7.1. Company overview
    • 7.7.2. Key executives
    • 7.7.3. Company snapshot
    • 7.7.4. Operating business segments
    • 7.7.5. Product portfolio
  • 7.8. AbbVie Inc.
    • 7.8.1. Company overview
    • 7.8.2. Key executives
    • 7.8.3. Company snapshot
    • 7.8.4. Operating business segments
    • 7.8.5. Product portfolio
    • 7.8.6. Business performance
  • 7.9. Brii Biosciences
    • 7.9.1. Company overview
    • 7.9.2. Key executives
    • 7.9.3. Company snapshot
    • 7.9.4. Operating business segments
    • 7.9.5. Product portfolio
    • 7.9.6. Business performance
  • 7.10. Shionogi & Co., Ltd.
    • 7.10.1. Company overview
    • 7.10.2. Key executives
    • 7.10.3. Company snapshot
    • 7.10.4. Operating business segments
    • 7.10.5. Product portfolio
    • 7.10.6. Business performance
    • 7.10.7. Key strategic moves and developments